3 Cardiovascular Medicines Leader, Innovation Led Generics Company and Anti Retroviral Ingredients Specialist Stocks With a Strong Future Roadmap: Torrent Pharmaceuticals, Glenmark Pharmaceuticals and Laurus Labs

Heart care medicine and API pharma stocks let investors follow companies that serve a growing part of the Indian economy. Torrent Pharmaceuticals, Glenmark Pharmaceuticals and Laurus Labs cover a cardiovascular medicines leader, an innovation led generics company and an anti retroviral ingredients specialist.

This list covers three heart care medicine and API pharma stocks with complete current figures: Torrent Pharmaceuticals, Glenmark Pharmaceuticals and Laurus Labs. Every figure comes from the latest reported financials and the 28 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Heart Care Medicine and API Pharma Stocks?

Heart care medicine and API pharma stocks are listed companies that make and sell branded medicines for heart, brain and stomach care, build generics and new drug programmes for India and global markets and produce active ingredients and finished formulations. Their earnings depend on prescription growth, new launches and regulatory approvals.

Heart Care Medicine and API Pharma Stocks at a Glance

On valuation, Glenmark Pharmaceuticals trades at a P/E below the industry P/E, while Torrent Pharmaceuticals and Laurus Labs trade above it, which reflects the growth the market already expects. Readers comparing heart care medicine and API pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in heart care medicine and API pharma stocks can use the coming numbers to test whether growth is holding.

Why Do Heart Care Medicine and API Pharma Stocks Have a Strong Roadmap in India?

Heart care medicine and API pharma stocks have a strong roadmap in India because rising healthcare spending, wider insurance cover and steady growth in chronic care keep expanding the market for these medicines and ingredient makers.

• Chronic care demand. Long term therapies create repeat prescriptions.
• Global reach. Sales in many countries spread earnings across markets.
• Pipeline depth. New launches and ingredients widen the product range.

Why Torrent Pharmaceuticals Features Among These Heart Care Medicine and API Pharma Stocks

Among the heart care medicine and API pharma stocks on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.

Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%.

In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0.

Roadmap: The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.

What to watch: Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.

Why Glenmark Pharmaceuticals Features Among These Heart Care Medicine and API Pharma Stocks

Among the research led pharma shares on this list, Glenmark Pharmaceuticals is a research-driven pharma company with branded generics in India and other emerging markets, generics in the United States and Europe, and an innovation arm focused on new drugs.

In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%.

Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7.

Roadmap: The company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.

What to watch: Track new product launches, progress in the innovation pipeline and balance sheet strength.

Why Laurus Labs Features Among These Heart Care Medicine and API Pharma Stocks

Among the three companies on this list, Laurus Labs is a Hyderabad-based pharmaceutical company with businesses in active ingredients, finished formulations, custom synthesis and biotechnology, with a leading position in anti-retroviral medicines.

The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0.

Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore.

Roadmap: The company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.

What to watch: Follow the ramp-up of new capacity in formulations and the order flow in custom synthesis.

Torrent Pharmaceuticals vs Glenmark Pharmaceuticals vs Laurus Labs on Key Financials

The table below sets the three heart care medicine and API pharma stocks side by side on revenue, profit and margin, using reported figures.

Glenmark Pharmaceuticals posts the highest return on equity in this group at 28.1%. Glenmark Pharmaceuticals has the largest FY26 revenue at Rs 17,443 crore, and Torrent Pharmaceuticals shows the fastest revenue growth with a 12.4% compound annual rate. A useful habit with heart care medicine and API pharma stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several medicines and ingredient stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Heart Care Medicine and API Pharma Stocks

Every theme carries risks that deserve a check before any decision. For these heart care medicine and API pharma stocks, the main points are: Long-term research led pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Pricing pressure. Generic prices can change by market.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter heart care medicine and API pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Heart Care Medicine and API Pharma Stocks

Heart care medicine and API pharma stocks reward investors who follow demand trends, order books and margins together. Torrent Pharmaceuticals, Glenmark Pharmaceuticals and Laurus Labs each have a clear plan to grow. Based on the 28 October 2026 close, Torrent Pharmaceuticals trades at Rs 4,557, Glenmark Pharmaceuticals at Rs 2,300 and Laurus Labs at Rs 2,181.9. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these heart care medicine and API pharma stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track heart care medicine and API pharma stocks, set price alerts and get research-backed stock ideas.

What are heart care medicine and API pharma stocks?

Ans. Heart care medicine and API pharma stocks are listed companies that make and sell branded medicines for heart, brain and stomach care, build generics and new drug programmes for India and global markets and produce active ingredients and finished formulations. Their earnings depend on prescription growth, new launches and regulatory approvals. This list looks at three of them, Torrent Pharmaceuticals, Glenmark Pharmaceuticals and Laurus Labs, using reported FY22 to FY26 financials and the 28 October 2026 closing prices.

Which heart care medicine and API pharma stocks are covered in this list?

Ans. This list covers Torrent Pharmaceuticals, Glenmark Pharmaceuticals and Laurus Labs. Based on the 28 October 2026 close, Torrent Pharmaceuticals traded at Rs 4,557, Glenmark Pharmaceuticals at Rs 2,300 and Laurus Labs at Rs 2,181.9. Their return on equity ranges from 16.8% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 12.4%.

Why do heart care medicine and API pharma stocks have a strong future roadmap in India?

Ans. Heart care medicine and API pharma stocks have a strong roadmap in India because rising healthcare spending, wider insurance cover and steady growth in chronic care keep expanding the market for these medicines and ingredient makers. The main drivers are as follows. Chronic care demand. Long term therapies create repeat prescriptions. Global reach. Sales in many countries spread earnings across markets. Pipeline depth. New launches and ingredients widen the product range. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Torrent Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.

How has Glenmark Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7. Looking ahead, the company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.

How has Laurus Labs performed financially?

Ans. Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0. Looking ahead, the company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.

What risks should investors check before buying heart care medicine and API pharma stocks?

Ans. Investors should check a few risks before buying heart care medicine and API pharma stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of heart care medicine and API pharma stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 28 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.